Roila F, Basurto C, Bracarda S, Picciafuoco M, Ballatori E, Del Favero A, Tonato M
Divisione Oncologia Medica, Ospedale Policlinico, Perugia, Italia.
Oncology. 1990;47(5):415-7. doi: 10.1159/000226860.
In a pilot study we evaluated the efficacy and tolerability of a four-drug antiemetic combination (metoclopramide, dexamethasone, diphenhydramine and lorazepam) in cancer patients submitted to cisplatin chemotherapy at doses greater than or equal to 50 mg/m2. Fifty male patients entered the study. Complete protection from vomiting and nausea was obtained in 41 patients (82%) (95% confidence limits 71 and 93%). Toxicity was slight except for moderate sedation in 10% of patients necessitating their hospitalization. Only one extrapyramidal reaction (akathisia) was observed. When these results were compared to our previous experience in male patients treated with a combination of metoclopramide, dexamethasone and diphenhydramine without lorazepam, used at the same doses and schedule, no clear benefit and higher toxicity was observed.
在一项初步研究中，我们评估了一种四联抗呕吐药物组合（胃复安、地塞米松、苯海拉明和劳拉西泮）对接受剂量大于或等于50mg/m²顺铂化疗的癌症患者的疗效和耐受性。50名男性患者进入该研究。41名患者（82%）（95%置信区间为71%和93%）实现了完全预防呕吐和恶心。除10%的患者出现中度镇静需住院治疗外，毒性轻微。仅观察到1例锥体外系反应（静坐不能）。将这些结果与我们之前使用相同剂量和方案的胃复安、地塞米松和苯海拉明组合（未使用劳拉西泮）治疗男性患者的经验进行比较时，未观察到明显益处且毒性更高。
